1-7 of 7
Fernando Salangsang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LB-326: The role of HER3 in HER2-amplified cancers other than breast cancers

Avisek Majumder, Veronica Steri, Fernando Salangsang, Mark Moasser
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): LB-326.
DOI: https://doi.org/10.1158/1538-7445.AM2020-LB-326
Published: 15 August 2020
View article
Journal Articles

Abstract LB-144: Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Meghna Das Thakur, Rosalie Fisher, Fernando Salangsang, Allison Landman, William Sellers, Nancy Pryer, Mitchell Paul Levesque, Reinhard Dummer, Martin Gore, James Larkin, Martin McMahon, Darrin Stuart
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): LB-144.
DOI: https://doi.org/10.1158/1538-7445.AM2013-LB-144
Published: 15 April 2013
View article
Journal Articles

Abstract SY17-03: Targeting BRAF and PI3′-kinase signaling for therapy of melanoma.

Martin McMahon, Meghna Das Thakur, Victoria Marsh, Jillian Silva, Allison Landman, Marian Deuker, Fernando Salangsang, Nancy Pryer, Wayne Phillips, Mitchell Levesque, Reinhard Dummer, Marcus Bosenberg, William R. Sellers, Darrin Stuart
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): SY17-03.
DOI: https://doi.org/10.1158/1538-7445.AM2013-SY17-03
Published: 15 April 2013
View article
Journal Articles

Abstract 5592: Modeling the evolution of resistance to RAF inhibitors in clinically relevant melanoma models

Meghna Das Thakur, Fernando Salangsang, Nancy Pryer, Darrin Stuart, Martin McMahon
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 5592.
DOI: https://doi.org/10.1158/1538-7445.AM2012-5592
Published: 15 April 2012
View article
Journal Articles

Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor

Darrin D. Stuart, Nanxin Li, Daniel J. Poon, Kimberly Aardalen, Susan Kaufman, Hanne Merritt, Fernando Salangsang, Edward Lorenzana, Allen Li, Majid Ghoddusi, Giordano Caponigro, Frank Sun, Swarupa Kulkarni, Shefali Kakar, Nancy Turner, Richard Zang, John Tellew, Nancy Pryer
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3790.
DOI: https://doi.org/10.1158/1538-7445.AM2012-3790
Published: 15 April 2012
View article
Journal Articles

RAF265 is a potent Raf kinase inhibitor with selective anti-proliferative activity in vitro and in vivo

Darrin Stuart, Kimberly Aardalen, Eleni Venetsanakos, Tobi Nagel, Marco Wallroth, David Batt, Savithri Ramurthy, Daniel Poon, Michel Faure, Edward Lorenzana, Fernando Salangsang, Jeff Dove, Evelyn Garrett, Mina Aikawa, Angelo Kaplan, Payman Amiri, Paul Renhowe
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4876.
Published: 01 May 2008
View article
Journal Articles

CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models

Eleni Venetsanakos, Darrin Stuart, Nguyen Tan, Helen Ye, Fernando Salangsang, Kimberley Aardalen, Michel Faure, Carla Heise, Dirk Mendel, Bahija Jallal
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1140.
Published: 15 April 2006
View article